

Glenmark opens unit in Switzerland

PRESS TRUST OF INDIA

New Delhi

Glenmark Pharmaceuticals on Wednesday opened a new manufacturing facility in Switzerland for supply of clinical trial material.

Glenmark Pharmaceuticals, a wholly-owned subsidiary of the company has opened its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland, Glenmark Pharma said in a statement.

This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development, it added.

Glenmark Pharma Biologics-president Michael Buschle said "We have been doing cutting edge work in the area of novel monoclonal antibodies and have several monoclonal antibody candidates and bispecific antibodies in the pipeline. The manufacturing facility would help us bring these antibodies to the clinic faster".

Health issue

- This manufacturing facility supplements Glenmark's existing in-house discovery
- The focus for the biologics R&D centre is to develop novel biologic entities
- An antibody is a protein produced by plasma cells that is used by the body's immune

An antibody is a protein produced by plasma cells that is used by the body's immune system to identify and neutralise foreign particles such as bacteria and viruses.

The focus for the biologics R&D centre is to develop novel biologic entities for the treatment of pain, oncologic, inflammatory and respiratory conditions, Glenmark Pharma said.

Since its inception around 10 years back, Glenmark's biologics research centre has filed several patents on novel biologic entities, it added.

Company.

TD, NIC
17-6-14